We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genetic Profile Identified for Dementia with Lewy Bodies

By LabMedica International staff writers
Posted on 25 Dec 2017
Print article
Image: A histopathology of Lewy body inclusion (arrow) in a pigmented neuron of the substantia nigra located in the mid-brain (Photo courtesy of the Cleveland Clinic).
Image: A histopathology of Lewy body inclusion (arrow) in a pigmented neuron of the substantia nigra located in the mid-brain (Photo courtesy of the Cleveland Clinic).
Dementia with Lewy bodies has a unique genetic profile, distinct from those of Alzheimer's disease or Parkinson's disease, according to the first large-scale genetic study of this common type of dementia.

Dementia with Lewy bodies (DLB) is the second most common form of dementia in elderly people but has been overshadowed in the medical field, partly because of similarities between dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.

An international team of 65 scientists from 11 countries collaborated with those at University College London (London, UK) collected samples from white participants of European ancestry who had been diagnosed with dementia with Lewy bodies according to established clinical or pathological criteria. Pathological samples were ascertained following autopsy in each individual brain bank, whereas clinical samples were collected after participant examination. The team genotyped 1,743 patients with dementia with Lewy bodies (DLB), including both clinical samples and 1,324 pathological samples assessed post-mortem, and 4,454 controls.

The investigators found that two of the genetic loci that were found to be significantly associated with DLB, Apolipoprotein E (APOE) and glucocerebrosidase (GBA), bore the same associations to DLB as they do to Alzheimer's and Parkinson's, respectively. Another one of the loci identified alpha-synuclein (SNCA), is also associated with Parkinson's, but differently as the team found that a different part of the gene is linked to DLB. They also found preliminary evidence for a gene locus that had not been previously associated with DLB, but the results did not reach significance. The team also found that a few loci that are associated with Alzheimer's and Parkinson's do not appear to be associated with DLB. They were able to identify a heritability estimate of DLB for the first time, at 36%, which is similar to that of Parkinson's. The heritability was particularly high for four specific chromosomes, suggesting that further studies could focus on those chromosomes to identify novel loci.

Rita Guerreiroa, PhD, a senior lecturer and the lead author of the study said, “As the gene loci that had previously been associated with DLB were also implicated in Alzheimer's and Parkinson's, it was unclear if DLB's genetic roots were simply a combination of the other two diseases. We've confirmed that instead, it has its own unique genetic profile.” The study was published in the January 2018 edition of journal The Lancet Neurology.

Related Links:
University College London

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.